Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021

[1]  Akshay S. Desai,et al.  Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.

[2]  Deepak L. Bhatt,et al.  Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence , 2022, Diabetes, obesity & metabolism.

[3]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[4]  K. Iglay,et al.  Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK , 2022, BMJ Open Diabetes Research & Care.

[5]  E. Huang,et al.  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[6]  D. Prieto-Merino,et al.  Estimating proportion of days covered (PDC) using real-world online medicine suppliers’ datasets , 2021, Journal of pharmaceutical policy and practice.

[7]  Amy Alonzo,et al.  Proportion of days covered as a measure of medication adherence. , 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  G. Corrao,et al.  Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting. , 2021, Diabetes research and clinical practice.

[9]  J. Rosenstock,et al.  Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. , 2021, The New England journal of medicine.

[10]  G. Filippatos,et al.  Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. , 2021, Journal of the American College of Cardiology.

[11]  T. Wadden,et al.  Once-Weekly Semaglutide in Adults with Overweight or Obesity. , 2021, The New England journal of medicine.

[12]  K. Iglay,et al.  Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States , 2020, Patient preference and adherence.

[13]  Z. Ademi,et al.  Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysis , 2020, Diabetes/metabolism research and reviews.

[14]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[15]  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[16]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[17]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[18]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[19]  S. Solomon,et al.  Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus , 2018, Circulation.

[20]  14. Diabetes Care in the Hospital , 2016, Diabetes Care.

[21]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[22]  J. Hippisley-Cox,et al.  Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database , 2016, British Medical Journal.

[23]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[24]  L. Vo,et al.  Transitions of Care for People with Type 2 Diabetes: Utilization of Antihyperglycemic Agents Pre- and Post-Hospitalization , 2015, Diabetes Therapy.

[25]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[26]  Henrik Toft Sørensen,et al.  The Danish Civil Registration System as a tool in epidemiology , 2014, European Journal of Epidemiology.

[27]  J. Hallas,et al.  The Danish National Prescription Registry , 2011, Scandinavian journal of public health.

[28]  P. Mortensen,et al.  The Danish Civil Registration System. A cohort of eight million persons. , 2006, Danish medical bulletin.

[29]  L. Køber,et al.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. , 2006, European heart journal.